Doravirine and Hyoscyamine, Atropine, Scopolamine, and Phenobarbital
Determining the interaction of Doravirine and Hyoscyamine, Atropine, Scopolamine, and Phenobarbital and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:PHENobarbital may significantly reduce the blood levels of doravirine, which may make the medication less effective in treating HIV infection. Additionally, it may lead to development of viral resistance to this and various other HIV medications that are currently used for treatment. Doravirine should generally not be started until at least 4 weeks after discontinuing PHENobarbital. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:CONTRAINDICATED: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme. When a single 100 mg dose of doravirine was administered with the potent CYP450 3A4 inducer rifampin (600 mg once daily) in 10 study subjects, doravirine peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (C24hr) decreased by an average of 57%, 88% and 97%, respectively, compared to doravirine administered alone. Reduced efficacy of doravirine may occur.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with potent CYP450 3A4 inducers is considered contraindicated. At least a 4-week cessation period is recommended prior to initiation of doravirine treatment.
- "Product Information. Pifeltro (doravirine)." Merck & Company Inc, Whitehouse Station, NJ.
Generic Name: atropine / hyoscyamine / phenobarbital / scopolamine
Brand name: Donnatal, D-Tal, Phenohytro, Chardonna-2, Hyosophen, Donnapine, Elixiral, Bellatal, Spasmolin, Haponal, Antispas, Barbidonna, Donnatal Extentabs, Antispasmodic, Bellalphen, Donnaphen, Spasquid, Alkabel-SR, Bellatal ER, Servira, PB-Hyos, Quadrapax, Phenobarbital with Belladonna Alkaloids
Synonyms: Belladonna alkaloids and phenobarbital
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Doravirine-Hyoscyamine, Atropine, Scopolamine, and Phenobarbital Elixir
- Doravirine-Hyoscyamine, Atropine, Scopolamine, and Phenobarbital Tablets
- Doravirine-Hyoscyamine, methenamine, methylene blue, and sodium biphosphate
- Doravirine-Hyoscyamine, Methenamine, Methylene Blue, and Sodium Phosphate Monobasic
- Doravirine-Hyoscyamine, methenamine, methylene blue, phenyl salicylate, and sodium phosphate
- Doravirine-Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate
- Hyoscyamine, Atropine, Scopolamine, and Phenobarbital-Doravirine, lamivudine, and tenofovir
- Hyoscyamine, Atropine, Scopolamine, and Phenobarbital-Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
- Hyoscyamine, Atropine, Scopolamine, and Phenobarbital-Doribax
- Hyoscyamine, Atropine, Scopolamine, and Phenobarbital-Doripenem
- Hyoscyamine, Atropine, Scopolamine, and Phenobarbital-Doripenem Intravenous
- Hyoscyamine, Atropine, Scopolamine, and Phenobarbital-Dornase Alfa